vs
MFA FINANCIAL, INC.（MFA）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
RIGEL PHARMACEUTICALS INC的季度营收约是MFA FINANCIAL, INC.的1.3倍（$69.8M vs $55.5M），RIGEL PHARMACEUTICALS INC同比增速更快（21.2% vs 9.2%），过去两年RIGEL PHARMACEUTICALS INC的营收复合增速更高（53.7% vs 7.7%）
MFA Financial是总部位于美国的房地产投资信托（REIT），核心业务为投资及管理住宅与商业抵押贷款支持证券、抵押贷款及其他不动产相关金融资产，面向美国本土机构和个人投资者，通过审慎的资产筛选与风控机制追求稳定的经风险调整后收益。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
MFA vs RIGL — 直观对比
营收规模更大
RIGL
是对方的1.3倍
$55.5M
营收增速更快
RIGL
高出12.0%
9.2%
两年增速更快
RIGL
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $55.5M | $69.8M |
| 净利润 | — | $268.1M |
| 毛利率 | — | 91.5% |
| 营业利润率 | 97.9% | 33.2% |
| 净利率 | — | 384.0% |
| 营收同比 | 9.2% | 21.2% |
| 净利润同比 | — | 1769.2% |
| 每股收益（稀释后） | $0.43 | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MFARIGL
| Q4 25 | $55.5M | $69.8M | ||
| Q3 25 | $56.8M | $69.5M | ||
| Q2 25 | $61.3M | $101.7M | ||
| Q1 25 | $57.5M | $53.3M | ||
| Q4 24 | $50.8M | $57.6M | ||
| Q3 24 | $50.6M | $55.3M | ||
| Q2 24 | $53.5M | $36.8M | ||
| Q1 24 | $47.8M | $29.5M |
净利润MFARIGL
| Q4 25 | — | $268.1M | ||
| Q3 25 | $48.1M | $27.9M | ||
| Q2 25 | $33.2M | $59.6M | ||
| Q1 25 | $41.2M | $11.4M | ||
| Q4 24 | — | $14.3M | ||
| Q3 24 | $48.2M | $12.4M | ||
| Q2 24 | $41.9M | $-1.0M | ||
| Q1 24 | $23.2M | $-8.2M |
毛利率MFARIGL
| Q4 25 | — | 91.5% | ||
| Q3 25 | — | 93.2% | ||
| Q2 25 | — | 95.6% | ||
| Q1 25 | — | 91.7% | ||
| Q4 24 | — | 89.9% | ||
| Q3 24 | — | 85.5% | ||
| Q2 24 | — | 92.4% | ||
| Q1 24 | — | 93.1% |
营业利润率MFARIGL
| Q4 25 | 97.9% | 33.2% | ||
| Q3 25 | 84.5% | 40.9% | ||
| Q2 25 | 54.5% | 60.1% | ||
| Q1 25 | 70.0% | 23.9% | ||
| Q4 24 | 6.8% | 28.9% | ||
| Q3 24 | 98.2% | 25.4% | ||
| Q2 24 | 79.1% | 1.2% | ||
| Q1 24 | 50.7% | -23.6% |
净利率MFARIGL
| Q4 25 | — | 384.0% | ||
| Q3 25 | 84.7% | 40.2% | ||
| Q2 25 | 54.2% | 58.6% | ||
| Q1 25 | 71.6% | 21.5% | ||
| Q4 24 | — | 24.9% | ||
| Q3 24 | 95.2% | 22.5% | ||
| Q2 24 | 78.4% | -2.8% | ||
| Q1 24 | 48.5% | -27.9% |
每股收益（稀释后）MFARIGL
| Q4 25 | $0.43 | $14.11 | ||
| Q3 25 | $0.35 | $1.46 | ||
| Q2 25 | $0.21 | $3.28 | ||
| Q1 25 | $0.31 | $0.63 | ||
| Q4 24 | $-0.01 | $0.82 | ||
| Q3 24 | $0.37 | $0.70 | ||
| Q2 24 | $0.32 | $-0.06 | ||
| Q1 24 | $0.14 | $-0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $213.2M | $155.0M |
| 总债务越低越好 | — | $52.5M |
| 股东权益账面价值 | $1.8B | $391.5M |
| 总资产 | $13.0B | $513.6M |
| 负债/权益比越低杠杆越低 | — | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资MFARIGL
| Q4 25 | $213.2M | $155.0M | ||
| Q3 25 | $305.2M | $137.1M | ||
| Q2 25 | $275.7M | $108.4M | ||
| Q1 25 | $253.7M | $77.1M | ||
| Q4 24 | $338.9M | $77.3M | ||
| Q3 24 | $305.6M | $61.1M | ||
| Q2 24 | $289.4M | $49.1M | ||
| Q1 24 | $306.3M | $49.5M |
总债务MFARIGL
| Q4 25 | — | $52.5M | ||
| Q3 25 | — | $60.0M | ||
| Q2 25 | — | $60.0M | ||
| Q1 25 | — | $60.0M | ||
| Q4 24 | — | $60.0M | ||
| Q3 24 | — | $60.0M | ||
| Q2 24 | — | $60.0M | ||
| Q1 24 | — | $60.0M |
股东权益MFARIGL
| Q4 25 | $1.8B | $391.5M | ||
| Q3 25 | $1.8B | $117.6M | ||
| Q2 25 | $1.8B | $81.9M | ||
| Q1 25 | $1.8B | $18.6M | ||
| Q4 24 | $1.8B | $3.3M | ||
| Q3 24 | $1.9B | $-14.6M | ||
| Q2 24 | $1.9B | $-29.9M | ||
| Q1 24 | $1.9B | $-31.7M |
总资产MFARIGL
| Q4 25 | $13.0B | $513.6M | ||
| Q3 25 | $12.1B | $242.5M | ||
| Q2 25 | $11.7B | $206.7M | ||
| Q1 25 | $11.5B | $176.0M | ||
| Q4 24 | $11.4B | $164.0M | ||
| Q3 24 | $11.2B | $139.4M | ||
| Q2 24 | $11.1B | $128.4M | ||
| Q1 24 | $10.9B | $126.5M |
负债/权益比MFARIGL
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | 0.51× | ||
| Q2 25 | — | 0.73× | ||
| Q1 25 | — | 3.23× | ||
| Q4 24 | — | 18.25× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $76.2M | $22.0M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 0.08× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流MFARIGL
| Q4 25 | $76.2M | $22.0M | ||
| Q3 25 | $14.7M | $24.0M | ||
| Q2 25 | $38.5M | $30.5M | ||
| Q1 25 | $-14.6M | $-893.0K | ||
| Q4 24 | $200.1M | $14.5M | ||
| Q3 24 | $-11.3M | $21.7M | ||
| Q2 24 | $46.5M | $302.0K | ||
| Q1 24 | $53.5M | $-5.0M |
现金转化率MFARIGL
| Q4 25 | — | 0.08× | ||
| Q3 25 | 0.31× | 0.86× | ||
| Q2 25 | 1.16× | 0.51× | ||
| Q1 25 | -0.35× | -0.08× | ||
| Q4 24 | — | 1.01× | ||
| Q3 24 | -0.23× | 1.75× | ||
| Q2 24 | 1.11× | — | ||
| Q1 24 | 2.30× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
